Product Description
BSI-075 is an anti-PVRIG humanized antibody with high selectivity and high affinity. It demonstrated 10x higher binding affinity to PVRIG and 3x higher cell-based bioactivity compared to a COM701 analog. Inhibiting PVRIG leads to enhanced activation of T and NK cells and results in tumor growth inhibition. Biosion has global rights to develop and commercialize BSI-075. (Sourced from: https://www.biosion.com/pipeline)
Mechanisms of Action: PVRIG Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biosion
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|